Revivicor's Vision

Revivicor (successor to PPL Therapeutics) collaborated with the Roslin Institute to establish the world’s first cloned mammal

Revivicor (successor of PPL Therapeutics) produced the world’s first cloned pigs

Revivicor (successor to PPL Therapeutics) established the world’s first alpha-gal knockout pigs, the GalSafe™ lineage progenitors. The GalSafe™ line has one gene inactivated and this line is free of the epitope galactose alpha-1-3 galactose (alpha-gal)

Revivicor formed as a spin-out from PPL Therapeutics

Revivicor acquired by United Therapeutics Corporation to create an unlimited supply of manufactured organs for transplantation

Revivicor received a first-of-its-kind approval from the FDA for use of the GalSafe™ pig as a source of food for human consumption, and as a source of human therapeutics

Revivicor's UKidney™ from a pig was transplanted into the body of a recently deceased human maintained on artificial support UKidney™ is a development-stage product not approved for sale in any jurisdiction

A UHeart™ from a Revivicor pig was used clinically and established a new record for longest surviving recipient of a xenotransplantation productUHeart™ is a development-stage product not approved for sale in any jurisdiction

A UThymoKidney™ from a Revivicor pig was used in the longest-to-date documented case of a genetically-engineered pig kidney functioning in a human body. UThymoKidney™ is a development-stage product not approved for sale in any jurisdiction

A UHeart™ from a Revivicor pig was used clinically in a second human recipient UHeart™ is a development-stage product not approved for sale in any jurisdiction

The first detailed overview of the current state of the xenotransplantation industry is published in Physiological Reviews. The review collects the vast history of the technology used to generate genetically engineered pigs and the research conducted to date on the xenotransplantation of porcine hearts and kidneys.